3k5v › Citations

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS
Nature 463 501-6 (2010)
Cited: 349 times
EuropePMC logo PMID: 20072125

Abstract

In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor. Here, using solution NMR, X-ray crystallography, mutagenesis and hydrogen exchange mass spectrometry, we show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site. GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, when used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochemical and cellular assays against T315I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model. These results show that therapeutically relevant inhibition of Bcr-Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.

Reviews - 3k5v mentioned but not cited (11)

  1. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. ACS Chem Biol 9 1230-1241 (2014)
  2. Ten things you should know about protein kinases: IUPHAR Review 14. Fabbro D, Cowan-Jacob SW, Moebitz H. Br J Pharmacol 172 2675-2700 (2015)
  3. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Hantschel O, Grebien F, Superti-Furga G. Cancer Res 72 4890-4895 (2012)
  4. Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. Yueh C, Rettenmaier J, Xia B, Hall DR, Alekseenko A, Porter KA, Barkovich K, Keseru G, Whitty A, Wells JA, Vajda S, Kozakov D. J Med Chem 62 6512-6524 (2019)
  5. SPLINTS: small-molecule protein ligand interface stabilizers. Fischer ES, Park E, Eck MJ, Thomä NH. Curr Opin Struct Biol 37 115-122 (2016)
  6. Mechanism of activation and the rewired network: New drug design concepts. Nussinov R, Zhang M, Maloney R, Tsai CJ, Yavuz BR, Tuncbag N, Jang H. Med Res Rev 42 770-799 (2022)
  7. Computational methods for analysis and inference of kinase/inhibitor relationships. Ferrè F, Palmeri A, Helmer-Citterich M. Front Genet 5 196 (2014)
  8. Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. Arter C, Trask L, Ward S, Yeoh S, Bayliss R. J Biol Chem 298 102247 (2022)
  9. Druggable Transient Pockets in Protein Kinases. Umezawa K, Kii I. Molecules 26 651 (2021)
  10. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K. J Mol Biol 434 167626 (2022)
  11. Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, Jarrar Q, Ming LC. Biomolecules 12 878 (2022)

Articles - 3k5v mentioned but not cited (34)

  1. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Nature 463 501-506 (2010)
  2. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, Gray NS, Lindquist S. Nat Biotechnol 31 630-637 (2013)
  3. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Cancer Res 79 4744-4753 (2019)
  4. Moving Beyond Active-Site Detection: MixMD Applied to Allosteric Systems. Ghanakota P, Carlson HA. J Phys Chem B 120 8685-8695 (2016)
  5. Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation. Shimokawa K, Shibata N, Sameshima T, Miyamoto N, Ujikawa O, Nara H, Ohoka N, Hattori T, Cho N, Naito M. ACS Med Chem Lett 8 1042-1047 (2017)
  6. Expanding the diversity of allosteric bcr-abl inhibitors. Deng X, Okram B, Ding Q, Zhang J, Choi Y, Adrián FJ, Wojciechowski A, Zhang G, Che J, Bursulaya B, Cowan-Jacob SW, Rummel G, Sim T, Gray NS. J Med Chem 53 6934-6946 (2010)
  7. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Meirson T, Genna A, Lukic N, Makhnii T, Alter J, Sharma VP, Wang Y, Samson AO, Condeelis JS, Gil-Henn H. Oncotarget 9 22158-22183 (2018)
  8. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Piazza I, Beaton N, Bruderer R, Knobloch T, Barbisan C, Chandat L, Sudau A, Siepe I, Rinner O, de Souza N, Picotti P, Reiter L. Nat Commun 11 4200 (2020)
  9. Convolutional neural network scoring and minimization in the D3R 2017 community challenge. Sunseri J, King JE, Francoeur PG, Koes DR, Koes DR. J Comput Aided Mol Des 33 19-34 (2019)
  10. Updates to Binding MOAD (Mother of All Databases): Polypharmacology Tools and Their Utility in Drug Repurposing. Smith RD, Clark JJ, Ahmed A, Orban ZJ, Dunbar JB, Carlson HA. J Mol Biol 431 2423-2433 (2019)
  11. A novel quantitative kinase assay using bacterial surface display and flow cytometry. Henriques ST, Thorstholm L, Huang YH, Getz JA, Daugherty PS, Craik DJ. PLoS One 8 e80474 (2013)
  12. MixMD Probeview: Robust Binding Site Prediction from Cosolvent Simulations. Graham SE, Leja N, Carlson HA. J Chem Inf Model 58 1426-1433 (2018)
  13. pocketZebra: a web-server for automated selection and classification of subfamily-specific binding sites by bioinformatic analysis of diverse protein families. Suplatov D, Kirilin E, Arbatsky M, Takhaveev V, Svedas V. Nucleic Acids Res 42 W344-9 (2014)
  14. Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. Tanneeru K, Guruprasad L. PLoS One 8 e78556 (2013)
  15. Virtual target screening: validation using kinase inhibitors. Santiago DN, Pevzner Y, Durand AA, Tran M, Scheerer RR, Daniel K, Sung SS, Woodcock HL, Guida WC, Brooks WH. J Chem Inf Model 52 2192-2203 (2012)
  16. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. Frett B, Moccia M, Carlomagno F, Santoro M, Li HY. Eur J Med Chem 86 714-723 (2014)
  17. Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. Niggenaber J, Heyden L, Grabe T, Müller MP, Lategahn J, Rauh D. ACS Med Chem Lett 11 2484-2490 (2020)
  18. The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors. Malarz K, Mularski J, Pacholczyk M, Musiol R. Cancers (Basel) 12 E536 (2020)
  19. Computational Analysis of Crystallization Additives for the Identification of New Allosteric Sites. Fogha J, Diharce J, Obled A, Aci-Sèche S, Bonnet P. ACS Omega 5 2114-2122 (2020)
  20. FTMove: A Web Server for Detection and Analysis of Cryptic and Allosteric Binding Sites by Mapping Multiple Protein Structures. Egbert M, Jones G, Collins MR, Kozakov D, Vajda S. J Mol Biol 434 167587 (2022)
  21. Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl. Singh VK, Coumar MS. J Mol Model 23 218 (2017)
  22. How Diverse Are the Protein-Bound Conformations of Small-Molecule Drugs and Cofactors? Friedrich NO, Simsir M, Kirchmair J. Front Chem 6 68 (2018)
  23. Imatinib can act as an Allosteric Activator of Abl Kinase. Xie T, Saleh T, Rossi P, Miller D, Kalodimos CG. J Mol Biol 434 167349 (2022)
  24. Intermolecular Interactions in Crystal Structures of Imatinib-Containing Compounds. Vologzhanina AV, Ushakov IE, Korlyukov AA. Int J Mol Sci 21 E8970 (2020)
  25. Structure-guided optimization of small molecule c-Abl activators. Hong X, Cao P, Washio Y, Simpson G, Campobasso N, Yang J, Borthwick J, Burton G, Chabanet J, Bertrand S, Evans H, Young RJ, Qu J, Li H, Cottom J, Ward P, Zhang H, Ho T, Qin D, Christensen S, Head MS. J Comput Aided Mol Des 28 75-87 (2014)
  26. Mapping the conformational energy landscape of Abl kinase using ClyA nanopore tweezers. Li F, Fahie MA, Gilliam KM, Pham R, Chen M. Nat Commun 13 3541 (2022)
  27. Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to. Carofiglio F, Trisciuzzi D, Gambacorta N, Leonetti F, Stefanachi A, Nicolotti O. Molecules 25 E4210 (2020)
  28. C─H⋯O hydrogen bonds in kinase-inhibitor interfaces. Derewenda ZS, Hawro I, Derewenda U. IUBMB Life 72 1233-1242 (2020)
  29. Diversity-guided Lamarckian random drift particle swarm optimization for flexible ligand docking. Li C, Sun J, Palade V. BMC Bioinformatics 21 286 (2020)
  30. Divide-and-conquer strategy for large-scale Eulerian solvent excluded surface. Zhao R, Wang M, Tong Y, Wei GW. Commun Inf Syst 18 299-329 (2018)
  31. Low potency toxins reveal dense interaction networks in metabolism. Bains W. BMC Syst Biol 10 19 (2016)
  32. Congress 26th Annual GP2A Medicinal Chemistry Conference & 32nd Journées Franco-Belges de Pharmacochimie. Dallemagne P, Rochais C, Marchand P, Besson T. Pharmaceuticals (Basel) 12 E73 (2019)
  33. Predicting allosteric pockets in protein biological assemblages. Kumar A, Kaynak BT, Dorman KS, Doruker P, Jernigan RL. Bioinformatics 39 btad275 (2023)
  34. Structural mechanism of a drug-binding process involving a large conformational change of the protein target. Ayaz P, Lyczek A, Paung Y, Mingione VR, Iacob RE, de Waal PW, Engen JR, Seeliger MA, Shan Y, Shaw DE. Nat Commun 14 1885 (2023)


Reviews citing this publication (111)

  1. Tumour heterogeneity and resistance to cancer therapies. Dagogo-Jack I, Shaw AT. Nat Rev Clin Oncol 15 81-94 (2018)
  2. Targeting MET in cancer: rationale and progress. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Nat Rev Cancer 12 89-103 (2012)
  3. Allostery in disease and in drug discovery. Nussinov R, Tsai CJ. Cell 153 293-305 (2013)
  4. Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. Tonks NK. FEBS J 280 346-378 (2013)
  5. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Nat Rev Cancer 13 559-571 (2013)
  6. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Kell DB. Arch Toxicol 84 825-889 (2010)
  7. Pushing the limits of targeted therapy in chronic myeloid leukaemia. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Nat Rev Cancer 12 513-526 (2012)
  8. ABL tyrosine kinases: evolution of function, regulation, and specificity. Colicelli J. Sci Signal 3 re6 (2010)
  9. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Dar AC, Shokat KM. Annu Rev Biochem 80 769-795 (2011)
  10. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. Pagliarini R, Shao W, Sellers WR. EMBO Rep 16 280-296 (2015)
  11. Biophysics in drug discovery: impact, challenges and opportunities. Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H. Nat Rev Drug Discov 15 679-698 (2016)
  12. Dynamics-Driven Allostery in Protein Kinases. Kornev AP, Taylor SS. Trends Biochem Sci 40 628-647 (2015)
  13. Trends in kinase drug discovery: targets, indications and inhibitor design. Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Nat Rev Drug Discov 20 839-861 (2021)
  14. Targeting tumour-supportive cellular machineries in anticancer drug development. Dobbelstein M, Moll U. Nat Rev Drug Discov 13 179-196 (2014)
  15. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. Rossari F, Minutolo F, Orciuolo E. J Hematol Oncol 11 84 (2018)
  16. Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Wei H, Mo J, Tao L, Russell RJ, Tymiak AA, Chen G, Iacob RE, Engen JR. Drug Discov Today 19 95-102 (2014)
  17. Aurora kinase inhibitors as anticancer molecules. Katayama H, Sen S. Biochim Biophys Acta 1799 829-839 (2010)
  18. Natural course and biology of CML. Chereda B, Melo JV. Ann Hematol 94 Suppl 2 S107-21 (2015)
  19. Targeting protein lipidation in disease. Resh MD. Trends Mol Med 18 206-214 (2012)
  20. AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Arencibia JM, Pastor-Flores D, Bauer AF, Schulze JO, Biondi RM. Biochim Biophys Acta 1834 1302-1321 (2013)
  21. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Coutinho I, Day TK, Tilley WD, Selth LA. Endocr Relat Cancer 23 T179-T197 (2016)
  22. Mechanisms of drug resistance in kinases. Barouch-Bentov R, Sauer K. Expert Opin Investig Drugs 20 153-208 (2011)
  23. The GIST paradigm: lessons for other kinase-driven cancers. Antonescu CR. J Pathol 223 251-261 (2011)
  24. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Mol Cancer 17 49 (2018)
  25. Protein Lipidation in Cell Signaling and Diseases: Function, Regulation, and Therapeutic Opportunities. Chen B, Sun Y, Niu J, Jarugumilli GK, Wu X. Cell Chem Biol 25 817-831 (2018)
  26. Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. Laraia L, McKenzie G, Spring DR, Venkitaraman AR, Huggins DJ. Chem Biol 22 689-703 (2015)
  27. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Bernt KM, Bernt KM, Hunger SP. Front Oncol 4 54 (2014)
  28. The Philadelphia chromosome in leukemogenesis. Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, Liu Q. Chin J Cancer 35 48 (2016)
  29. Harnessing allostery: a novel approach to drug discovery. Lu S, Li S, Zhang J. Med Res Rev 34 1242-1285 (2014)
  30. Multifunctional Abl kinases in health and disease. Khatri A, Wang J, Pendergast AM. J Cell Sci 129 9-16 (2016)
  31. Critical role of actin-associated proteins in smooth muscle contraction, cell proliferation, airway hyperresponsiveness and airway remodeling. Tang DD. Respir Res 16 134 (2015)
  32. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Nair RR, Tolentino J, Hazlehurst LA. Biochem Pharmacol 80 602-612 (2010)
  33. Structure and dynamic regulation of Abl kinases. Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE. J Biol Chem 288 5443-5450 (2013)
  34. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. F1000Res 7 82 (2018)
  35. PI3K inhibitors: review and new strategies. Zhang M, Jang H, Nussinov R. Chem Sci 11 5855-5865 (2020)
  36. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. Medves S, Demoulin JB. J Cell Mol Med 16 237-248 (2012)
  37. The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Pophali PA, Patnaik MM. Cancer J 22 40-50 (2016)
  38. αC helix displacement as a general approach for allosteric modulation of protein kinases. Palmieri L, Rastelli G. Drug Discov Today 18 407-414 (2013)
  39. Anticancer drug resistance: An update and perspective. Nussinov R, Tsai CJ, Jang H. Drug Resist Updat 59 100796 (2021)
  40. Prospects for pharmacological targeting of pseudokinases. Kung JE, Jura N. Nat Rev Drug Discov 18 501-526 (2019)
  41. Signal transduction therapy of cancer. Levitzki A, Klein S. Mol Aspects Med 31 287-329 (2010)
  42. Drug discovery and the human kinome: recent trends. Eglen R, Reisine T. Pharmacol Ther 130 144-156 (2011)
  43. Using NMR to study fast dynamics in proteins: methods and applications. Sapienza PJ, Lee AL. Curr Opin Pharmacol 10 723-730 (2010)
  44. An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. Masson GR, Jenkins ML, Burke JE. Expert Opin Drug Discov 12 981-994 (2017)
  45. Understanding resistance to combination chemotherapy. Pritchard JR, Lauffenburger DA, Hemann MT. Drug Resist Updat 15 249-257 (2012)
  46. Cancer genetics and the cardiotoxicity of the therapeutics. Lal H, Kolaja KL, Force T. J Am Coll Cardiol 61 267-274 (2013)
  47. Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry. Huang RY, Chen G. Anal Bioanal Chem 406 6541-6558 (2014)
  48. Management of chronic myeloid leukemia in blast crisis. Saußele S, Silver RT. Ann Hematol 94 Suppl 2 S159-65 (2015)
  49. Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O. Biochim Biophys Acta 1834 1449-1459 (2013)
  50. Bioinformatics and variability in drug response: a protein structural perspective. Lahti JL, Tang GW, Capriotti E, Liu T, Altman RB. J R Soc Interface 9 1409-1437 (2012)
  51. Pseudokinases: update on their functions and evaluation as new drug targets. Byrne DP, Foulkes DM, Eyers PA. Future Med Chem 9 245-265 (2017)
  52. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Roskoski R. Pharmacol Res 117 20-31 (2017)
  53. Blind prediction of HIV integrase binding from the SAMPL4 challenge. Mobley DL, Liu S, Lim NM, Wymer KL, Perryman AL, Forli S, Deng N, Su J, Branson K, Olson AJ. J Comput Aided Mol Des 28 327-345 (2014)
  54. Protein X-ray Crystallography and Drug Discovery. Maveyraud L, Mourey L. Molecules 25 E1030 (2020)
  55. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. Leroy E, Constantinescu SN. Leukemia 31 1023-1038 (2017)
  56. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Eide CA, O'Hare T. Curr Hematol Malig Rep 10 158-166 (2015)
  57. Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. de Oliveira GA, Rangel LP, Costa DC, Silva JL. Front Oncol 5 97 (2015)
  58. Molecular biology of chronic myeloid leukemia. Maru Y. Cancer Sci 103 1601-1610 (2012)
  59. Biology-driven cancer drug development: back to the future. Lord CJ, Ashworth A. BMC Biol 8 38 (2010)
  60. Chronic myeloid leukemia: overview of new agents and comparative analysis. Jain P, Kantarjian H, Cortes J. Curr Treat Options Oncol 14 127-143 (2013)
  61. Small molecule probes of cellular pathways and networks. Castoreno AB, Eggert US. ACS Chem Biol 6 86-94 (2011)
  62. Targeted inhibition of kinases in cancer therapy. Baker SJ, Reddy EP. Mt Sinai J Med 77 573-586 (2010)
  63. Development of an effective therapy for chronic myelogenous leukemia. Woessner DW, Lim CS, Deininger MW. Cancer J 17 477-486 (2011)
  64. PROTACs to address the challenges facing small molecule inhibitors. Martín-Acosta P, Xiao X. Eur J Med Chem 210 112993 (2021)
  65. Targeting the MAPK Pathway in RAS Mutant Cancers. Hymowitz SG, Malek S. Cold Spring Harb Perspect Med 8 a031492 (2018)
  66. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Zhang H, Li S. Protein Cell 4 186-196 (2013)
  67. DNA damage stress response in germ cells: role of c-Abl and clinical implications. Gonfloni S. Oncogene 29 6193-6202 (2010)
  68. Fluorescent biosensors for high throughput screening of protein kinase inhibitors. Prével C, Pellerano M, Van TN, Morris MC. Biotechnol J 9 253-265 (2014)
  69. Mutational analysis in chronic myeloid leukemia: when and what to do? Branford S, Hughes TP. Curr Opin Hematol 18 111-116 (2011)
  70. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads. Bergsdorf C, Ottl J. Expert Opin Drug Discov 5 1095-1107 (2010)
  71. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Singh AP, Umbarkar P, Tousif S, Lal H. Int J Cardiol 316 214-221 (2020)
  72. Fluorescent Reporters and Biosensors for Probing the Dynamic Behavior of Protein Kinases. González-Vera JA, Morris MC. Proteomes 3 369-410 (2015)
  73. Going for broke: targeting the human cancer pseudokinome. Bailey FP, Byrne DP, McSkimming D, Kannan N, Eyers PA. Biochem J 465 195-211 (2015)
  74. A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Agnello S, Brand M, Chellat MF, Gazzola S, Riedl R. Angew Chem Int Ed Engl 58 3300-3345 (2019)
  75. Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition. Nussinov R, Zhang M, Tsai CJ, Jang H. Mol Cancer Res 19 543-548 (2021)
  76. Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery. Bian Y, Jun JJ, Cuyler J, Xie XQ. Eur J Med Chem 206 112690 (2020)
  77. Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Karvela M, Helgason GV, Holyoake TL. Expert Rev Anticancer Ther 12 381-392 (2012)
  78. Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. Burke MR, Smith AR, Zheng G. Front Cell Dev Biol 10 872729 (2022)
  79. Third-generation tyrosine kinase inhibitors and beyond. Quintás-Cardama A, Kantarjian H, Cortes J. Semin Hematol 47 371-380 (2010)
  80. Allosteric Regulation at the Crossroads of New Technologies: Multiscale Modeling, Networks, and Machine Learning. Verkhivker GM, Agajanian S, Hu G, Tao P. Front Mol Biosci 7 136 (2020)
  81. Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies. Oladejo M, Paterson Y, Wood LM. Front Immunol 12 642316 (2021)
  82. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. Inoue A, Kobayashi CI, Shinohara H, Miyamoto K, Yamauchi N, Yuda J, Akao Y, Minami Y. Int J Hematol 108 365-370 (2018)
  83. Declaration of Bcr-Abl1 independence. Zhao H, Deininger MW. Leukemia 34 2827-2836 (2020)
  84. Enhanced interrogation: emerging strategies for cell signaling inhibition. Huang R, Martinez-Ferrando I, Cole PA. Nat Struct Mol Biol 17 646-649 (2010)
  85. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. Hojjat-Farsangi M. J Drug Target 24 192-211 (2016)
  86. Update on emerging treatments for chronic myeloid leukemia. Fava C, Morotti A, Dogliotti I, Saglio G, Rege-Cambrin G. Expert Opin Emerg Drugs 20 183-196 (2015)
  87. Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer. Jones JK, Thompson EM. Mol Cancer Ther 19 1763-1769 (2020)
  88. A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Gnanasambandan K, Sayeski PP. Curr Med Chem 18 4659-4673 (2011)
  89. Advances in MS Based Strategies for Probing Ligand-Target Interactions: Focus on Soft Ionization Mass Spectrometric Techniques. Chen G, Fan M, Liu Y, Sun B, Liu M, Wu J, Li N, Guo M. Front Chem 7 703 (2019)
  90. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs. Nussinov R, Zhang M, Maloney R, Liu Y, Tsai CJ, Jang H. J Mol Biol 434 167569 (2022)
  91. Genie in a bottle: controlled release helps tame natural polypharmacology? Long MJ, Liu X, Aye Y. Curr Opin Chem Biol 51 48-56 (2019)
  92. Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. Luttman JH, Colemon A, Mayro B, Pendergast AM. Cell Commun Signal 19 59 (2021)
  93. The Intersection of Structural and Chemical Biology - An Essential Synergy. Zuercher WJ, Elkins JM, Knapp S. Cell Chem Biol 23 173-182 (2016)
  94. An overview of kinase downregulators and recent advances in discovery approaches. Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. Signal Transduct Target Ther 6 423 (2021)
  95. Brain tumor immunotherapy: seeing the brain in the body. Lampson LA. Drug Discov Today 18 399-406 (2013)
  96. Chemical kinomics: a powerful strategy for target deconvolution. Kim DH, Sim T. BMB Rep 43 711-719 (2010)
  97. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases. Prével C, Kurzawa L, Van TN, Morris MC. Eur J Med Chem 88 74-88 (2014)
  98. Current status of agents active against the T315I chronic myeloid leukemia phenotype. Burke AC, Swords RT, Kelly K, Giles FJ. Expert Opin Emerg Drugs 16 85-103 (2011)
  99. HDX-MS takes centre stage at unravelling kinase dynamics. Lorenzen K, Pawson T. Biochem Soc Trans 42 145-150 (2014)
  100. Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment. Wieczorek A, Uharek L. Biomark Insights 10 49-54 (2015)
  101. Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. DiNitto JP, Wu JC. Crit Rev Biochem Mol Biol 46 295-309 (2011)
  102. The impact of structural biology in medicine illustrated with four case studies. Hu T, Sprague ER, Fodor M, Stams T, Clark KL, Cowan-Jacob SW. J Mol Med (Berl) 96 9-19 (2018)
  103. Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. Weisberg E, Nonami A, Griffin JD. Arch Toxicol 88 2233-2242 (2014)
  104. Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia. Fernandes A, Shanmuganathan N, Branford S. Cancers (Basel) 14 620 (2022)
  105. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. Al Hamad M. F1000Res 10 1288 (2021)
  106. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. Perrone S, Massaro F, Alimena G, Breccia M. Expert Opin Pharmacother 17 1517-1526 (2016)
  107. Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, Soverini S. Onco Targets Ther 15 103-116 (2022)
  108. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies. Ng JJ, Ong ST. Curr Hematol Malig Rep 17 181-197 (2022)
  109. Allosteric regulation and inhibition of protein kinases. Mingione VR, Paung Y, Outhwaite IR, Seeliger MA. Biochem Soc Trans 51 373-385 (2023)
  110. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. Leukemia 37 2150-2167 (2023)
  111. Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery. Zhao Z, Bourne PE. Pharmaceuticals (Basel) 15 1322 (2022)

Articles citing this publication (193)

  1. The promise and peril of chemical probes. Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ. Nat Chem Biol 11 536-541 (2015)
  2. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F. Nat Med 21 440-448 (2015)
  3. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR. Nature 543 733-737 (2017)
  4. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Krishnan N, Koveal D, Miller DH, Xue B, Akshinthala SD, Kragelj J, Jensen MR, Gauss CM, Page R, Blackledge M, Muthuswamy SK, Peti W, Tonks NK. Nat Chem Biol 10 558-566 (2014)
  5. Activation pathway of Src kinase reveals intermediate states as targets for drug design. Shukla D, Meng Y, Roux B, Pande VS. Nat Commun 5 3397 (2014)
  6. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. Proc Natl Acad Sci U S A 107 12469-12474 (2010)
  7. Dynamic architecture of a protein kinase. McClendon CL, Kornev AP, Gilson MK, Taylor SS. Proc Natl Acad Sci U S A 111 E4623-31 (2014)
  8. Myristoylation and membrane binding regulate c-Src stability and kinase activity. Patwardhan P, Resh MD. Mol Cell Biol 30 4094-4107 (2010)
  9. Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy. Masterson LR, Shi L, Metcalfe E, Gao J, Taylor SS, Veglia G. Proc Natl Acad Sci U S A 108 6969-6974 (2011)
  10. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Chaikuad A, Tacconi EM, Zimmer J, Liang Y, Gray NS, Tarsounas M, Knapp S. Nat Chem Biol 10 853-860 (2014)
  11. Deciphering the structural basis of eukaryotic protein kinase regulation. Meharena HS, Chang P, Keshwani MM, Oruganty K, Nene AK, Kannan N, Taylor SS, Kornev AP. PLoS Biol 11 e1001680 (2013)
  12. The ins and outs of selective kinase inhibitor development. Müller S, Chaikuad A, Gray NS, Knapp S. Nat Chem Biol 11 818-821 (2015)
  13. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ. Pharmacol Rev 66 918-947 (2014)
  14. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA. Cancer Discov 9 926-943 (2019)
  15. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Blood 117 3151-3162 (2011)
  16. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. Sisk JM, Frieman MB, Machamer CE. J Gen Virol 99 619-630 (2018)
  17. Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Hartnett JR, Ingold MR, Zimmerman K, Machleidt T, Kirkland TA, Huwiler KG, Ohana RF, Slater M, Otto P, Cong M, Wells CI, Berger BT, Hanke T, Glas C, Ding K, Drewry DH, Huber KVM, Willson TM, Knapp S, Müller S, Meisenheimer PL, Fan F, Wood KV, Robers MB. Cell Chem Biol 25 206-214.e11 (2018)
  18. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. Cell 147 306-319 (2011)
  19. A public-private partnership to unlock the untargeted kinome. Knapp S, Arruda P, Blagg J, Burley S, Drewry DH, Edwards A, Fabbro D, Gillespie P, Gray NS, Kuster B, Lackey KE, Mazzafera P, Tomkinson NC, Willson TM, Workman P, Zuercher WJ. Nat Chem Biol 9 3-6 (2013)
  20. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW. Cancer Cell 36 431-443.e5 (2019)
  21. Conformational states dynamically populated by a kinase determine its function. Xie T, Saleh T, Rossi P, Kalodimos CG. Science 370 eabc2754 (2020)
  22. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, Galbraith S, Ho T, Zhang H, Hong X, Ward P, Hofmann G, Siegfried B, Zappacosta F, Washio Y, Cao P, Qu J, Bertrand S, Wang DY, Head MS, Li H, Moores S, Lai Z, Johanson K, Burton G, Erickson-Miller C, Simpson G, Tummino P, Copeland RA, Oliff A. Chem Biol 18 177-186 (2011)
  23. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. Cancer Res 71 3189-3195 (2011)
  24. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, Branford S. J Clin Oncol 29 4250-4259 (2011)
  25. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Dobson CL, Devine PW, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, van der Walle CF, Thornton P, Vinall L, Lowne D, Aagaard A, Olsson LL, Ridderstad Wollberg A, Welsh F, Karamanos TK, Pashley CL, Iadanza MG, Ranson NA, Ashcroft AE, Kippen AD, Vaughan TJ, Radford SE, Lowe DC. Sci Rep 6 38644 (2016)
  26. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S. Proc Natl Acad Sci U S A 110 E4437-45 (2013)
  27. Abl family kinases regulate endothelial barrier function in vitro and in mice. Chislock EM, Pendergast AM. PLoS One 8 e85231 (2013)
  28. Structure, regulation, signaling, and targeting of abl kinases in cancer. Hantschel O. Genes Cancer 3 436-446 (2012)
  29. Structural basis of p38α regulation by hematopoietic tyrosine phosphatase. Francis DM, Różycki B, Koveal D, Hummer G, Page R, Peti W. Nat Chem Biol 7 916-924 (2011)
  30. Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. Dixit A, Verkhivker GM. PLoS Comput Biol 7 e1002179 (2011)
  31. The ins and outs of bcr-abl inhibition. Reddy EP, Aggarwal AK. Genes Cancer 3 447-454 (2012)
  32. Detection of secondary binding sites in proteins using fragment screening. Ludlow RF, Verdonk ML, Saini HK, Tickle IJ, Jhoti H. Proc Natl Acad Sci U S A 112 15910-15915 (2015)
  33. Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis. Li J, Wei H, Krystek SR, Bond D, Brender TM, Cohen D, Feiner J, Hamacher N, Harshman J, Huang RY, Julien SH, Lin Z, Moore K, Mueller L, Noriega C, Sejwal P, Sheppard P, Stevens B, Chen G, Tymiak AA, Gross ML, Schneeweis LA. Anal Chem 89 2250-2258 (2017)
  34. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. Iacob RE, Zhang J, Gray NS, Engen JR. PLoS One 6 e15929 (2011)
  35. Structure of a Ca2+-myristoyl switch protein that controls activation of a phosphatidylinositol 4-kinase in fission yeast. Lim S, Strahl T, Thorner J, Ames JB. J Biol Chem 286 12565-12577 (2011)
  36. Fluorine-protein interactions and ¹⁹F NMR isotropic chemical shifts: An empirical correlation with implications for drug design. Dalvit C, Vulpetti A. ChemMedChem 6 104-114 (2011)
  37. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Cowan-Jacob SW, Jahnke W, Knapp S. Future Med Chem 6 541-561 (2014)
  38. Role of Abl in airway hyperresponsiveness and airway remodeling. Cleary RA, Wang R, Wang T, Tang DD. Respir Res 14 105 (2013)
  39. The Emerging Role of ABL Kinases in Solid Tumors. Wang J, Pendergast AM. Trends Cancer 1 110-123 (2015)
  40. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Shibata N, Miyamoto N, Nagai K, Shimokawa K, Sameshima T, Ohoka N, Hattori T, Imaeda Y, Nara H, Cho N, Naito M. Cancer Sci 108 1657-1666 (2017)
  41. c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M. Cell Rep 12 1006-1018 (2015)
  42. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Rettenmaier TJ, Sadowsky JD, Thomsen ND, Chen SC, Doak AK, Arkin MR, Wells JA. Proc Natl Acad Sci U S A 111 18590-18595 (2014)
  43. ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. Wang J, Rouse C, Jasper JS, Pendergast AM. Sci Signal 9 ra12 (2016)
  44. A myristoyl/phosphoserine switch controls cAMP-dependent protein kinase association to membranes. Gaffarogullari EC, Masterson LR, Metcalfe EE, Traaseth NJ, Balatri E, Musa MM, Mullen D, Distefano MD, Veglia G. J Mol Biol 411 823-836 (2011)
  45. Allosteric targeting of receptor tyrosine kinases. De Smet F, Christopoulos A, Carmeliet P. Nat Biotechnol 32 1113-1120 (2014)
  46. Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases? Gonfloni S, Maiani E, Di Bartolomeo C, Diederich M, Cesareni G. Int J Cell Biol 2012 683097 (2012)
  47. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T. Leukemia 27 118-129 (2013)
  48. Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis. Gu JJ, Rouse C, Xu X, Wang J, Onaitis MW, Pendergast AM. JCI Insight 1 e89647 (2016)
  49. Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. Lovera S, Morando M, Pucheta-Martinez E, Martinez-Torrecuadrada JL, Saladino G, Gervasio FL. PLoS Comput Biol 11 e1004578 (2015)
  50. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. Andreotti V, Ciribilli Y, Monti P, Bisio A, Lion M, Jordan J, Fronza G, Menichini P, Resnick MA, Inga A. PLoS One 6 e20643 (2011)
  51. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Schönbrunn E. ACS Chem Biol 7 698-706 (2012)
  52. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO. Neuro Oncol 13 759-766 (2011)
  53. Atomic view of the energy landscape in the allosteric regulation of Abl kinase. Saleh T, Rossi P, Kalodimos CG. Nat Struct Mol Biol 24 893-901 (2017)
  54. The human kinome and kinase inhibition. Duong-Ly KC, Peterson JR. Curr Protoc Pharmacol Chapter 2 Unit2.9 (2013)
  55. A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry. Maier KE, Jangra RK, Shieh KR, Cureton DK, Xiao H, Snapp EL, Whelan SP, Chandran K, Levy M. Mol Ther Nucleic Acids 5 e321 (2016)
  56. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M. J Med Chem 54 2610-2626 (2011)
  57. Role of c-Abl tyrosine kinase in smooth muscle cell migration. Cleary RA, Wang R, Waqar O, Singer HA, Tang DD. Am J Physiol Cell Physiol 306 C753-61 (2014)
  58. A critical comparative assessment of predictions of protein-binding sites for biologically relevant organic compounds. Chen K, Mizianty MJ, Gao J, Kurgan L. Structure 19 613-621 (2011)
  59. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. Corrado C, Flugy AM, Taverna S, Raimondo S, Guggino G, Karmali R, De Leo G, Alessandro R. PLoS One 7 e42310 (2012)
  60. Induction of M2-like macrophages in recipient NOD-scid mice by allogeneic donor CD4(+)CD25(+) regulatory T cells. Hu X, Liu G, Hou Y, Shi J, Zhu L, Jin D, Peng J, Zhao Y. Cell Mol Immunol 9 464-472 (2012)
  61. A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. Hoj JP, Mayro B, Pendergast AM. Cell Rep 29 3421-3434.e8 (2019)
  62. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R. J Biol Chem 288 25254-25264 (2013)
  63. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. Huang WC, Tsai CC, Chen CL, Chen TY, Chen YP, Lin YS, Lu PJ, Lin CM, Wang SH, Tsao CW, Wang CY, Cheng YL, Hsieh CY, Tseng PC, Lin CF. FASEB J 25 3661-3673 (2011)
  64. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC. PLoS One 10 e0131400 (2015)
  65. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, Force T, Becker JR, Lal H. Cardiovasc Res 115 966-977 (2019)
  66. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Sci Rep 5 14538 (2015)
  67. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Sengupta A, Ficker AM, Dunn SK, Madhu M, Cancelas JA. Blood 119 494-502 (2012)
  68. The energy landscape analysis of cancer mutations in protein kinases. Dixit A, Verkhivker GM. PLoS One 6 e26071 (2011)
  69. Using small molecules to target protein phosphatases. Vintonyak VV, Waldmann H, Rauh D. Bioorg Med Chem 19 2145-2155 (2011)
  70. Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis. La Sala G, Decherchi S, De Vivo M, Rocchia W. ACS Cent Sci 3 949-960 (2017)
  71. Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Hossain S, Dubielecka PM, Sikorski AF, Birge RB, Kotula L. Genes Cancer 3 402-413 (2012)
  72. Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. Panjarian S, Iacob RE, Chen S, Wales TE, Engen JR, Smithgall TE. J Biol Chem 288 6116-6129 (2013)
  73. Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry. Engen JR, Wales TE, Chen S, Marzluff EM, Hassell KM, Weis DD, Smithgall TE. Int Rev Phys Chem 32 96-127 (2013)
  74. Protein conformation as a regulator of cell-matrix adhesion. Hytönen VP, Wehrle-Haller B. Phys Chem Chem Phys 16 6342-6357 (2014)
  75. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. Cell Rep 25 449-463.e4 (2018)
  76. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design. Panigrahi S, Stetefeld J, Jangamreddy JR, Mandal S, Mandal SK, Los M. PLoS One 7 e28395 (2012)
  77. Small molecule regulation of protein conformation by binding in the Flap of HIV protease. Tiefenbrunn T, Forli S, Baksh MM, Chang MW, Happer M, Lin YC, Perryman AL, Rhee JK, Torbett BE, Olson AJ, Elder JH, Finn MG, Stout CD. ACS Chem Biol 8 1223-1231 (2013)
  78. Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. Qiu Y, Yin X, Li X, Wang Y, Fu Q, Huang R, Lu S. Pharmaceutics 13 747 (2021)
  79. Dynamics of protein kinases: insights from nuclear magnetic resonance. Xiao Y, Liddle JC, Pardi A, Ahn NG. Acc Chem Res 48 1106-1114 (2015)
  80. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. Nyfeler B, Chen Y, Li X, Pinzon-Ortiz M, Wang Z, Reddy A, Pradhan E, Das R, Lehár J, Schlegel R, Finan PM, Cao ZA, Murphy LO, Huang A. PLoS One 7 e48548 (2012)
  81. Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models. Meng Y, Gao C, Clawson DK, Atwell S, Russell M, Vieth M, Roux B. J Chem Theory Comput 14 2721-2732 (2018)
  82. Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. Marit MR, Chohan M, Matthew N, Huang K, Kuntz DA, Rose DR, Barber DL. PLoS One 7 e43437 (2012)
  83. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization. Resetca D, Haftchenary S, Gunning PT, Wilson DJ. J Biol Chem 289 32538-32547 (2014)
  84. Conformational equilibrium of N-myristoylated cAMP-dependent protein kinase A by molecular dynamics simulations. Cembran A, Masterson LR, McClendon CL, Taylor SS, Gao J, Veglia G. Biochemistry 51 10186-10196 (2012)
  85. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. Salah E, Ugochukwu E, Barr AJ, von Delft F, Knapp S, Elkins JM. J Med Chem 54 2359-2367 (2011)
  86. Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. Li R, Knight JF, Park M, Pendergast AM. PLoS One 10 e0124960 (2015)
  87. Allosteric modulation of a human protein kinase with monobodies. Zorba A, Nguyen V, Koide A, Hoemberger M, Zheng Y, Kutter S, Kim C, Koide S, Kern D. Proc Natl Acad Sci U S A 116 13937-13942 (2019)
  88. BCR-ABL1 kinase: hunting an elusive target with new weapons. Skorski T. Chem Biol 18 1352-1353 (2011)
  89. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH. Acta Pharmacol Sin 35 401-409 (2014)
  90. Letter Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Blood 124 153-155 (2014)
  91. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Stuart DD, Sellers WR. Nat Med 19 538-540 (2013)
  92. Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap. Corbi-Verge C, Marinelli F, Zafra-Ruano A, Ruiz-Sanz J, Luque I, Faraldo-Gómez JD. Proc Natl Acad Sci U S A 110 E3372-80 (2013)
  93. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. Wang F, Hou W, Chitsike L, Xu Y, Bettler C, Perera A, Bank T, Cotler SJ, Dhanarajan A, Denning MF, Ding X, Breslin P, Qiang W, Li J, Koleske AJ, Qiu W. Gastroenterology 159 289-305.e16 (2020)
  94. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. Greuber EK, Pendergast AM. J Immunol 189 5382-5392 (2012)
  95. Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38α kinase. Getlik M, Simard JR, Termathe M, Grütter C, Rabiller M, van Otterlo WA, Rauh D. PLoS One 7 e39713 (2012)
  96. Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization. Mohanty S, Oruganty K, Kwon A, Byrne DP, Ferries S, Ruan Z, Hanold LE, Katiyar S, Kennedy EJ, Eyers PA, Kannan N. PLoS Genet 12 e1005885 (2016)
  97. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T. Leukemia 31 2844-2847 (2017)
  98. The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions. Yamani A, Wu D, Waggoner L, Noah T, Koleske AJ, Finkelman F, Hogan SP. J Allergy Clin Immunol 142 1159-1172.e5 (2018)
  99. c-Abl tyrosine kinase regulates cytokinesis of human airway smooth muscle cells. Chen S, Tang DD. Am J Respir Cell Mol Biol 50 1076-1083 (2014)
  100. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy. Wang F, Li S, Gan T, Stott GM, Flint A, Chou TF. ChemMedChem 15 685-694 (2020)
  101. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity. Lorenz S, Deng P, Hantschel O, Superti-Furga G, Kuriyan J. Biochem J 468 283-291 (2015)
  102. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Vakana E, Sassano A, Platanias LC. Autophagy 6 966-967 (2010)
  103. Optimizing combination therapies with existing and future CML drugs. Katouli AA, Komarova NL. PLoS One 5 e12300 (2010)
  104. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. Oncotarget 9 13423-13437 (2018)
  105. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M. BMC Cancer 12 411 (2012)
  106. Completing the structural family portrait of the human EphB tyrosine kinase domains. Overman RC, Debreczeni JE, Truman CM, McAlister MS, Attwood TK. Protein Sci 23 627-638 (2014)
  107. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics. Ishikawa T, Hosaka YZ, Beckwitt C, Wells A, Oltvai ZN, Warita K. Oncotarget 9 29304-29315 (2018)
  108. Hybrid Mass Spectrometry Approaches to Determine How L-Histidine Feedback Regulates the Enzyzme MtATP-Phosphoribosyltransferase. Pacholarz KJ, Burnley RJ, Jowitt TA, Ordsmith V, Pisco JP, Porrini M, Larrouy-Maumus G, Garlish RA, Taylor RJ, de Carvalho LPS, Barran PE. Structure 25 730-738.e4 (2017)
  109. Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. Marcsisin SR, Engen JR. J Mol Biol 402 892-904 (2010)
  110. NMR Characterization of Information Flow and Allosteric Communities in the MAP Kinase p38γ. Aoto PC, Martin BT, Wright PE. Sci Rep 6 28655 (2016)
  111. A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain. Song GJ, Rahman MH, Jha MK, Gupta DP, Park SH, Kim JH, Lee SH, Lee IK, Sim T, Bae YC, Lee WH, Suk K. Front Pharmacol 10 543 (2019)
  112. Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Zhang H, Shen W, Rempel D, Monsey J, Vidavsky I, Gross ML, Bose R. Mol Cell Proteomics 10 M110.005678 (2011)
  113. Neutralizing positive charges at the surface of a protein lowers its rate of amide hydrogen exchange without altering its structure or increasing its thermostability. Shaw BF, Arthanari H, Narovlyansky M, Durazo A, Frueh DP, Pollastri MP, Lee A, Bilgicer B, Gygi SP, Wagner G, Whitesides GM. J Am Chem Soc 132 17411-17425 (2010)
  114. Sos1 Regulates Macrophage Podosome Assembly and Macrophage Invasive Capacity. Baruzzi A, Remelli S, Lorenzetto E, Sega M, Chignola R, Berton G. J Immunol 195 4900-4912 (2015)
  115. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. Gui F, Jiang J, He Z, Li L, Li Y, Deng Z, Lu Y, Wu X, Chen G, Su J, Song S, Zhang YM, Yun CH, Huang X, Weisberg E, Zhang J, Deng X. Br J Pharmacol 176 4491-4509 (2019)
  116. Letter Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Weisberg E, Deng X, Choi HG, Barrett R, Adamia S, Ray A, Moreno D, Kung AL, Gray N, Griffin JD. Leukemia 24 1375-1378 (2010)
  117. Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. Lee BJ, Shah NP. Leukemia 31 1096-1107 (2017)
  118. The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion. Dölker N, Górna MW, Sutto L, Torralba AS, Superti-Furga G, Gervasio FL. PLoS Comput Biol 10 e1003863 (2014)
  119. 19F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors. Skora L, Jahnke W. ACS Med Chem Lett 8 632-635 (2017)
  120. ABL kinase inhibition promotes lung regeneration through expansion of an SCGB1A1+ SPC+ cell population following bacterial pneumonia. Khatri A, Kraft BD, Tata PR, Randell SH, Piantadosi CA, Pendergast AM. Proc Natl Acad Sci U S A 116 1603-1612 (2019)
  121. Clarifying binding difference of ATP and ADP to extracellular signal-regulated kinase 2 by using molecular dynamics simulations. Chen J. Chem Biol Drug Des 89 548-558 (2017)
  122. Direct detection of structurally resolved dynamics in a multiconformation receptor-ligand complex. Carroll MJ, Gromova AV, Miller KR, Tang H, Wang XS, Tripathy A, Singleton SF, Collins EJ, Lee AL. J Am Chem Soc 133 6422-6428 (2011)
  123. Hydrogen-Deuterium Exchange and Hydroxyl Radical Footprinting for Mapping Hydrophobic Interactions of Human Bromodomain with a Small Molecule Inhibitor. Li KS, Schaper Bergman ET, Beno BR, Huang RY, Deyanova E, Chen G, Gross ML. J Am Soc Mass Spectrom 30 2795-2804 (2019)
  124. Synergistic Allostery in Multiligand-Protein Interactions. Ghode A, Gross LZF, Tee WV, Guarnera E, Berezovsky IN, Biondi RM, Anand GS. Biophys J 119 1833-1848 (2020)
  125. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. G Lindström HJ, Friedman R. BMC Cancer 20 397 (2020)
  126. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action. Navratilova I, Macdonald G, Robinson C, Hughes S, Mathias J, Phillips C, Cook A. J Biomol Screen 17 183-193 (2012)
  127. Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor are kinase independent and imatinib insensitive. Tabone-Eglinger S, Calderin-Sollet Z, Pinon P, Aebischer N, Wehrle-Haller M, Jacquier MC, Boettiger D, Wehrle-Haller B. FASEB J 28 4441-4456 (2014)
  128. Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian A, Metodieva A, Ruthardt M, Mahajna J. BMC Cancer 12 563 (2012)
  129. Comment Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance. Hantschel O. Haematologica 97 157-159 (2012)
  130. Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase. Hall J, Aulabaugh A, Rajamohan F, Liu S, Kaila N, Wan ZK, Ryan M, Magyar R, Qiu X. J Biol Chem 287 7717-7727 (2012)
  131. Detection of allosteric kinase inhibitors by displacement of active site probes. Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM. J Biomol Screen 17 813-821 (2012)
  132. Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery. Gul S, Gribbon P. Expert Opin Drug Discov 5 681-690 (2010)
  133. Fluorescence lifetime assays: current advances and applications in drug discovery. Pritz S, Doering K, Woelcke J, Hassiepen U. Expert Opin Drug Discov 6 663-670 (2011)
  134. Hierarchical Organization Endows the Kinase Domain with Regulatory Plasticity. Creixell P, Pandey JP, Palmeri A, Bhattacharyya M, Creixell M, Ranganathan R, Pincus D, Yaffe MB. Cell Syst 7 371-383.e4 (2018)
  135. Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Beyett TS, To C, Heppner DE, Rana JK, Schmoker AM, Jang J, De Clercq DJH, Gomez G, Scott DA, Gray NS, Jänne PA, Eck MJ. Nat Commun 13 2530 (2022)
  136. Selection of cyclic-peptide inhibitors targeting Aurora kinase A: problems and solutions. Shomin CD, Restituyo E, Cox KJ, Ghosh I. Bioorg Med Chem 19 6743-6749 (2011)
  137. Comprehensive assessment of nine docking programs on type II kinase inhibitors: prediction accuracy of sampling power, scoring power and screening power. Shen C, Wang Z, Yao X, Li Y, Lei T, Wang E, Xu L, Zhu F, Li D, Hou T. Brief Bioinform 21 282-297 (2020)
  138. Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design. Huang W, Nussinov R, Zhang J. Methods Mol Biol 1529 439-446 (2017)
  139. Design and synthesis of thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false positives to ATP-noncompetitive inhibitors. Radi M, Crespan E, Falchi F, Bernardo V, Zanoli S, Manetti F, Schenone S, Maga G, Botta M. ChemMedChem 5 1226-1231 (2010)
  140. Enhancing protein fold determination by exploring the complementary information of chemical cross-linking and coevolutionary signals. Dos Santos RN, Ferrari AJR, de Jesus HCR, Gozzo FC, Morcos F, Martínez L. Bioinformatics 34 2201-2208 (2018)
  141. Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function. Grover P, Shi H, Baumgartner M, Camacho CJ, Smithgall TE. PLoS One 10 e0133590 (2015)
  142. Editorial Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable". Hantschel O, Grebien F, Superti-Furga G. Oncotarget 2 828-829 (2011)
  143. ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Luttman JH, Hoj JP, Lin KH, Lin J, Gu JJ, Rouse C, Nichols AG, MacIver NJ, Wood KC, Pendergast AM. Cell Rep 37 109880 (2021)
  144. ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation. Khatri A, Gu JJ, McKernan CM, Xu X, Pendergast AM. Oncotarget 10 1874-1886 (2019)
  145. Defying c-Abl signaling circuits through small allosteric compounds. Gonfloni S. Front Genet 5 392 (2014)
  146. Development of WEE2 kinase inhibitors as novel non-hormonal female contraceptives that target meiosis†. Hanna CB, Mudaliar D, John K, Allen CL, Sun L, Hawkinson JE, Schönbrunn E, Georg GI, Jensen JT. Biol Reprod 103 368-377 (2020)
  147. EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells. Tripathi R, Liu Z, Plattner R. Curr Pharmacol Rep 4 367-379 (2018)
  148. Scaffold hopping enables direct access to more potent PROTACs with in vivo activity. Burslem GM, Bondeson DP, Crews CM. Chem Commun (Camb) 56 6890-6892 (2020)
  149. Abl kinase constructs expressed in bacteria: facilitation of structural and functional studies including segmental labeling by expressed protein ligation. Xu R, Liu D, Cowburn D. Mol Biosyst 8 1878-1885 (2012)
  150. Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis. Jiang A, Bao Y, Wang A, Gong W, Gan X, Wang J, Bao Y, Wu Z, Liu B, Lu J, Wang L. Oxid Med Cell Longev 2022 3617775 (2022)
  151. Imatinib and GNF-5 Exhibit an Inhibitory Effect on Growth of Hepatocellar Carcinoma Cells by Downregulating S-phase Kinase-associated Protein 2. Zhang H, Yi J, Yoon D, Ryoo Z, Lee I, Kim M. J Cancer Prev 25 252-257 (2020)
  152. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors. Beetham H, Griffith BGC, Murina O, Loftus AEP, Parry DA, Temps C, Culley J, Muir M, Unciti-Broceta A, Sims AH, Byron A, Brunton VG. Cancer Res 82 632-647 (2022)
  153. Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1. Zhang H, Zhu M, Li M, Ni D, Wang Y, Deng L, Du K, Lu S, Shi H, Cai C. Front Pharmacol 13 862504 (2022)
  154. Synthesis, kinetic studies and molecular modeling of novel tacrine dimers as cholinesterase inhibitors. de Aquino RA, Modolo LV, Alves RB, de Fátima Â. Org Biomol Chem 11 8395-8409 (2013)
  155. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M. Haematologica 97 251-257 (2012)
  156. A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. Lu Y, Fan Z, Zhu SJ, Huang X, Zhuang Z, Li Y, Deng Z, Gao L, Hong X, Zhang T, Li L, Sun X, Huang W, Zhang J, Liu Y, Zhang B, Jiang J, Gui F, Wang Z, Li Q, Song S, Huang X, Wu Q, Chen L, Zhou D, Zhang J, Yun CH, Chen L, Deng X. EMBO Mol Med 14 e14296 (2022)
  157. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site. Dong J, Lu W, Pan X, Su P, Shi Y, Wang J, Zhang J. Bioorg Med Chem 22 6876-6884 (2014)
  158. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance. El Rashedy AA, Olotu FA, Soliman MES. Chem Biodivers 15 e1700533 (2018)
  159. From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond. Kharas MG, Daley GQ. Genes Cancer 1 1164-1169 (2010)
  160. Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines. Najajreh Y, Khamaisie H, Ruimi N, Khatib S, Katzhendler J, Ruthardt M, Mahajna J. Mol Biol Rep 40 2205-2213 (2013)
  161. Abl family tyrosine kinases govern IgG extravasation in the skin in a murine pemphigus model. Ono S, Egawa G, Nomura T, Kitoh A, Dainichi T, Otsuka A, Nakajima S, Amagai M, Matsumoto F, Yamamoto M, Kubota Y, Takai T, Honda T, Kabashima K. Nat Commun 10 4432 (2019)
  162. Allosteric regulation of autoinhibition and activation of c-Abl. Liu Y, Zhang M, Tsai CJ, Jang H, Nussinov R. Comput Struct Biotechnol J 20 4257-4270 (2022)
  163. Challenges in pharmacology of anti-cancer drugs - the search for addictions. Feron O. Front Pharmacol 1 120 (2010)
  164. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase. Gao C, Grøtli M, Eriksson LA. J Mol Model 21 167 (2015)
  165. Computational dissection of allosteric inhibition of the SH2 domain of Bcr-Abl kinase by the monobody inhibitor AS25. Ji M, Zheng G, Li X, Zhang Z, Jv G, Wang X, Wang J. J Mol Model 23 183 (2017)
  166. Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib. Pan X, Dong J, Shao R, Su P, Shi Y, Wang J, He L. Bioorg Med Chem Lett 25 4164-4168 (2015)
  167. Identification of borrelidin binding site on threonyl-tRNA synthetase. Li M, Zhang J, Liu C, Fang B, Wang X, Xiang W. Biochem Biophys Res Commun 451 485-490 (2014)
  168. Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1. Ting PY, Damoiseaux R, Titz B, Bradley KA, Graeber TG, Fernández-Vega V, Bannister TD, Chase P, Nair R, Scampavia L, Hodder P, Spicer TP, Colicelli J. PLoS One 10 e0121833 (2015)
  169. Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. Packer L, Marais R. Cancer Cell 19 435-437 (2011)
  170. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. Melkus M, Bennaceur-Griscelli A, Valogne Y, Flamant S, Chomel JC, Sorel N, Bonnet ML, Deininger MW, Mitjavila-Garcia MT, Turhan AG. Exp Hematol 41 335-45.e3 (2013)
  171. Conformational landscape and low lying excited states of imatinib. Vinţeler E, Stan NF, Luchian R, Căinap C, Ramalho JP, Chiş V. J Mol Model 21 84 (2015)
  172. Determination of the binding mechanism of histone deacetylase inhibitors. Meyer-Almes FJ. Chem Biol Drug Des 93 1214-1250 (2019)
  173. Druggable exosites of the human kino-pocketome. Nicola G, Kufareva I, Ilatovskiy AV, Abagyan R. J Comput Aided Mol Des 34 219-230 (2020)
  174. IFITM proteins assist cellular uptake of diverse linked chemotypes. Lou K, Wassarman DR, Yang T, Paung Y, Zhang Z, O'Loughlin TA, Moore MK, Egan RK, Greninger P, Benes CH, Seeliger MA, Taunton J, Gilbert LA, Shokat KM. Science 378 1097-1104 (2022)
  175. Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells. Regev O, Kidan N, Nicola M, Khamisie H, Ruthardt M, Mahajna J. Arch Med Sci 17 266-274 (2021)
  176. Protocols for the Design of Kinase-focused Compound Libraries. Jacoby E, Wroblowski B, Buyck C, Neefs JM, Meyer C, Cummings MD, van Vlijmen H. Mol Inform 37 e1700119 (2018)
  177. Target Characterization of Kaempferol against Myocardial Infarction Using Novel In Silico Docking and DARTS Prediction Strategy. Wu X, Li X, Yang C, Diao Y. Int J Mol Sci 22 12908 (2021)
  178. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations. Mingione VR, Foda ZH, Paung Y, Philipose H, Rangwala AM, Shan Y, Seeliger MA. J Mol Biol 434 167628 (2022)
  179. 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion. Khamaisi H, Mahmoud H, Mahajna J. Molecules 27 804 (2022)
  180. A back-door insight into the modulation of Src kinase activity by the polyamine spermidine. Rossini S, Gargaro M, Scalisi G, Bianconi E, Ambrosino S, Panfili E, Volpi C, Orabona C, Macchiarulo A, Fallarino F, Mondanelli G. Elife 12 e85872 (2023)
  181. A biophysical framework for double-drugging kinases. Kim C, Ludewig H, Hadzipasic A, Kutter S, Nguyen V, Kern D. Proc Natl Acad Sci U S A 120 e2304611120 (2023)
  182. Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis. Liu B, Ding J, Liu Y, Wu J, Wu X, Chen Q, Li W. J Comput Aided Mol Des 37 325-338 (2023)
  183. Editorial Guest editorial: chronic myeloid leukemia. Minami Y. Int J Hematol 108 353-354 (2018)
  184. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Han HJ, Kim JJ, Pyne D, Travas A, Ambalavanan A, Kimura S, Deininger MW, Kim JW, Kim DDH. Leukemia (2023)
  185. Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma Expression. Malnassy G, Keating CR, Gad S, Bridgeman B, Perera A, Hou W, Cotler SJ, Ding X, Choudhry M, Sun Z, Koleske AJ, Qiu W. Cell Mol Gastroenterol Hepatol 16 685-709 (2023)
  186. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model. Langhammer M, Schöpf J, Jaquet T, Horn K, Angel M, Spohr C, Christen D, Uhl FM, Maié T, Jacobi H, Feyerabend TB, Huber J, Panning M, Sitaru C, Costa I, Zeiser R, Aumann K, Becker H, Braunschweig T, Koschmieder S, Shoumariyeh K, Huber M, Schemionek-Reinders M, Brummer T, Halbach S. Leukemia 37 1474-1484 (2023)
  187. Molecular Docking-Based Screening for Novel Inhibitors of the Human Immunodeficiency Virus Type 1 Protease that Effectively Reduce the Viral Replication in Human Cells. Mavian C, Coman RM, Zhang X, Pomeroy S, Ostrov DA, Dunn BM, Sleasman JW, Goodenow MM. J AIDS Clin Res 12 841 (2021)
  188. Non-tyrosine kinase inhibitor-targeting of BCR-ABL expressing cells. Frankfurt O, Platanias LC. Leuk Lymphoma 53 1857-1858 (2012)
  189. Src stimulates Abl-dependent phosphorylation of the guanine exchange factor Net1A to promote its cytosolic localization and cell motility. Sprenger A, Carr HS, Ulu A, Frost JA. J Biol Chem 299 104887 (2023)
  190. Strategies to generate biological reagents for kinase drug discovery. Hassan NJ, Gul S. Expert Opin Drug Discov 6 1215-1225 (2011)
  191. Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations. Malarz K, Mularski J, Pacholczyk M, Musiol R. J Enzyme Inhib Med Chem 38 2201410 (2023)
  192. Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase. Johnson TK, Bochar DA, Vandecan NM, Furtado J, Agius MP, Phadke S, Soellner MB. Angew Chem Int Ed Engl 60 20196-20199 (2021)
  193. News The other Achilles' heel of BCR-ABL1. De Keersmaecker K. Haematologica 97 2 (2012)


Quick links